contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Ultimovacs is a Norwegian pharmaceutical company. The company's business focus is to develop immunotherapies for various cancer conditions. Research and development are based on a self-based technological platform, where the products are mainly further developed as vaccines. The largest presence is in Europe and North America. Ultimovacs was founded in 2011 and is headquartered in Oslo.

Zelluna

Oslo, Norway, 25 March 2026 - Zelluna ASA, a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, announces...

Oslo, Norway, 25 March 2026 - Zelluna ASA, a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, announces that the Board of Directors of Zelluna ASA has approved the Annual Report for 2025.&nbsp; A PDF version of the Annual Report, as well as the report in European Single Electronic Format (ESEF), are attached to this release. The Annual Report is also available on the company's website: <a href="https://www.globenewswire.com/Tracker?data=IahfWdNFoFesTaDOD-tJK4bA0qmjHGLrVMfHqoR1VM9rts9xDg6esOndejQp4THBueoMMc-enGeKhHtCS0UTejtW4KCtxLMoGAg6KlVvelE=">www.zelluna.com</a> This information is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act. For further information, please contact: Anders Tuv, Chairman of the Board of Directors of Zelluna ASA Email: <a href="https://www.globenewswire.com/Tracker?data=1LFg5pjLXgRaCmPTKDvYJov1hDziTz2tgCOL1f8212gWJbhK_qpCk8e9qRDxt4kO10lq9bPG5DKwvq77-a9cvg==">at@radforsk.no</a> Phone: +47 982 06 826 Namir Hassan, CEO, Zelluna ASA Email: <a href="https://www.globenewswire.com/Tracker?data=MfUijUS6nqIQ41_xnHwchr2gQXvAttCA5Q_MPKP6tlJw8CeoWbbGfw_6184BFXnNf0T5kIqLU9iUMFCf2S21oLzxo5dJZ6kf1eeQ1oTzdlCNFHRKh7c9ICLOlDTI9aOp">namir.hassan@zelluna.com</a> Phone: +44 7720 687608 Geir Christian Melen, CFO, Zelluna ASA Email: <a href="https://www.globenewswire.com/Tracker?data=ZuZxPr79mso0CfxUslC1nDOKcf6KvmsXE284T6tPp1PGUwhWF6lsqX7dztEwTUw-ngLg0TQWf3lee1cDR4985paVKbtEEDps5wKzqM2DqXn9d-Xhk0vx8ccPCeCZaasiwyh4rBR3l-nxLK0qGF-P9g==">geir.christian.melen@zelluna.com</a> Phone: +47 913 02 965 Attachments<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/1c32338e-79ae-4b3c-92d2-ee2430ef7546">Zelluna Annual Report 2025</a> </li> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/d8725261-a8a1-4313-88e4-58f0a9d3d8ed">254900B4VALJZR9TL744-2025-12-31-1-en</a> </li> </ul><img alt="" src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE3MTg3MiM0MDIzNjMzODEjMjIwOTM5Mw=="> <img alt="" src="https://ml-eu.globenewswire.com/media/OWFhZjc0YzAtNzZhYS00ZDM0LWFhOTUtMjRhNWY3NTY2YWEwLTEyMjA5NDYtMjAyNi0wMy0yNS1lbg==/tiny/Zelluna-ASA.png">

Zelluna ASA [ZLNA]: Annual Report 2025

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Faron Pharmaceuticals

Herantis Pharma

Mendus

Probabilities of success in drug development

Nordea Bank

Aktionær i Nordea? Det er nemmere end nogensinde at deltage i Nordeas generalforsamling takket være nyt digitalt setup

Return on capital (ROE, ROI, ROIC, RONIC)

Balance sheet, debt leverage and risks